All In Biotech

NDA 021208 · Organon USA Organon

Remeron Soltab

Mirtazapine · Oral

Last checked: Nov 20, 2026Latest source record: Nov 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jan 12, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

25 Phase 3, 7 recruiting

FAERS reports

76,416

66,432 serious, 12,226 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . REMERON/REMERONSolTab is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. REMERON/REMERONSolTab is not approved for use in pediatric patients. ( 5.1 , 8.4 )

What it is approved for

From the label in effect Aug 6, 2025.

REMERON/REMERONSolTab are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ] . REMERON/REMERONSolTab is indicated for the treatment of major depressive disorder (MDD) in adults. ( 1 )

Mechanism: The mechanism of action of mirtazapine for the treatment of major depressive disorder, is unclear. However, its efficacy could be mediated through its activity as an antagonist at central presynaptic α 2 -adrenergic inhibitory autoreceptors and heteroreceptors and enhancing central noradrenergic and serotonergic activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • REMERON SOLTAB · MIRTAZAPINE 45MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • REMERON SOLTAB · MIRTAZAPINE 15MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • REMERON SOLTAB · MIRTAZAPINE 30MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mirtazapine" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue4,001
  • nausea3,967
  • drug ineffective3,857
  • toxicity to various agents3,802
  • fall3,461
  • off label use3,442
  • diarrhoea3,394
  • drug interaction3,117
  • dizziness2,985
  • death2,898
  • dyspnoea2,852
  • anxiety2,759

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004547
2005730
2006808
2007882
2008957
20091,143
20101,379
20111,836
20121,913
20131,817
20142,304
20152,879
20163,351
20173,947
20185,569
20196,224
20206,278
20215,491
20225,684
20235,871
20245,817
20256,213
20264,774

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 540 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.